NeuropAWAY
Diabetic Neuropathy
Vedic Lifesciences Pvt. Ltd.N/ADormant
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 95/ 100
Competitive context
28 Active assets in the Diabetic Neuropathy cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Duloxetine Aga Khan University | Phase 4 | A |
CYCLOHEXANEACETIC ACID, 1-(AMINOMETHYL)- Aziende Chimiche Riunite Angelini Francesco S.p.A | Phase 4 | BBB |
ds-5565 Bangladesh Medical University | Phase 4 | BBB |
Capsaicin Corporacion Parc Tauli | Phase 4 | BBB |
Pregabalin Shandong Suncadia Medicine Co., Ltd. | Phase 4 | BBB |
View all 50 →
Same molecule, other indications
NeuropAWAY is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →